Julia Degler, MD
Family Medicine · Greenfield, INNPI 1295996346
Payments from drug & device makers
Across 189 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$447
- Lilly USA, LLC$332
- Novo Nordisk$299
- Novartis$209
- GSK$208
- Astellas Pharma US Inc$201
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,125100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $447 |
| Lilly USA, LLC | 22 | $332 |
| Novo Nordisk | 22 | $299 |
| Novartis | 13 | $209 |
| GSK | 13 | $208 |
| Astellas Pharma US Inc | 10 | $201 |
| Pfizer | 12 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $190 |
| Boehringer Ingelheim | 9 | $147 |
| AstraZeneca | 8 | $108 |
| Phathom Pharmaceuticals, Inc. | 5 | $94 |
| Amarin Pharma, Inc. | 5 | $74 |
| Exact Sciences | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $66 |
| Bayer | 2 | $43 |
| Corium, LLC | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Abbott | 2 | $35 |
| Amgen | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $23 |
| Verona Pharma, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Circassia Inc. | 1 | $11 |
| Merck | 1 | $11 |
| Mayne Pharma Commercial LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$136
How this compares
$3,133 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $41,364 |
| XareltoRivaroxaban | 26 | $40,400 |
| EliquisApixaban | 27 | $37,170 |
| FarxigaDapagliflozin Propanediol | 23 | $31,645 |
| MyrbetriqMirabegron | 40 | $29,811 |
| JardianceEmpagliflozin | 26 | $27,655 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,717 |
| RybelsusSemaglutide | 12 | $15,210 |
| TradjentaLinagliptin | 20 | $12,041 |
| Spiriva RespimatTiotropium Bromide | 17 | $11,986 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $9,519 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,430 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,748 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $5,121 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 14 | $4,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $299 | $56,57453 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $147 | $51,68263 claims |
| Johnson & JohnsonXarelto | $23 | $40,40026 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $208 | $38,78979 claims |
| PfizerEliquis | $200 | $37,17027 claims |
| AstraZenecaFarxiga | $108 | $31,64523 claims |
| Astellas Pharma US IncMyrbetriq | $201 | $29,81140 claims |
| AbbVieSynthroid | $447 | $1,92533 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,702218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Greenfield
- Talessa PowellGreenfield$1.4M
- Thomas O'ConnorGreenfield$228K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.